Shares of Neon Therapeutics Inc (NASDAQ:NTGN) have earned an average recommendation of “Buy” from the six brokerages that are currently covering the company, MarketBeat.com reports. Five equities research analysts have rated the stock with a buy rating. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $18.08.

Several analysts have recently weighed in on NTGN shares. Cann reaffirmed a “buy” rating and issued a $20.00 target price on shares of Neon Therapeutics in a report on Tuesday, August 7th. LADENBURG THALM/SH SH started coverage on shares of Neon Therapeutics in a report on Monday, October 1st. They issued a “buy” rating and a $20.00 target price on the stock. Finally, Zacks Investment Research raised shares of Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 target price on the stock in a report on Friday, November 16th.

Shares of NASDAQ:NTGN traded down $0.17 during midday trading on Friday, hitting $6.20. The stock had a trading volume of 2,110 shares, compared to its average volume of 129,539. Neon Therapeutics has a 1 year low of $5.62 and a 1 year high of $16.23.

Neon Therapeutics (NASDAQ:NTGN) last issued its earnings results on Monday, November 12th. The company reported ($0.67) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.12. On average, equities analysts predict that Neon Therapeutics will post -5.32 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in NTGN. TRV GP Iii LLC purchased a new stake in Neon Therapeutics during the second quarter worth about $122,745,000. FMR LLC purchased a new stake in Neon Therapeutics during the second quarter worth about $26,746,000. Partner Fund Management L.P. purchased a new stake in Neon Therapeutics during the second quarter worth about $10,771,000. Partner Investment Management L.P. boosted its holdings in Neon Therapeutics by 32,903.8% during the third quarter. Partner Investment Management L.P. now owns 832,355 shares of the company’s stock worth $5,841,000 after buying an additional 829,833 shares in the last quarter. Finally, Hillhouse Capital Management Ltd. purchased a new stake in Neon Therapeutics during the second quarter worth about $8,969,000. 68.11% of the stock is currently owned by hedge funds and other institutional investors.

About Neon Therapeutics

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

See Also: How to calculate compound interest

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.